New figures published today (Wednesday 22 January 2020) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised £1.3 billion in 2019. The total is the third highest year recorded by the trade association and since 2012 investment has increased by over 400%
Commenting on the new NHS England/Novartis deal and the publication of the new UK life sciences sector update announced at JP Morgan today, Steve Bates OBE, Chief Executive of the BioIndustry Association said:
"Global players are announcing the UK as their destination of choice for innovation at this year’s JP Morgan Healthcare conference.
The BIA will be attending a number of international conferences and events in 2020, where we will be developing closer ties with partners and promoting the strengths of the UK life sciences and biotech cluster to an international audience.
Sharon Grimster of ReNeuron and Dr Sarah Goulding of the Knowledge Transfer Network (KTN) will be awarded the prestigious Peter Dunnill award and Richard Wilson impact award respectively, at the UK BioIndustry Association’s (BIA) 16th bioProcessUK conference in Liverpool later this month.
The United Kingdom (UK) will have a general election on Thursday, 12 December. The UK BioIndustry Association (BIA) has today launched a biotech manifesto with its recommendations on how political parties can support the innovative UK life sciences sector.
Steve Bates OBE, Chief Executive of the BioIndustry Association (BIA) said: “Thanks to new advances in science and innovation, we are at the cusp of a new industrial revolution, however Brexit is causing much uncertainty for UK SMEs. I welcome the publication of this important review and it is good to see the Science Minister recognising the valuable contribution the life sciences sector makes in discovering new cures for life-threatening diseases.
Steve Bates OBE, CEO of the BIA said: “We welcome today’s announcement that NHS England and Vertex have been able to reach a deal and that this drug will soon be available to patients and their families. This is one of a number of deals that the NHS has reached with industry to bring life-saving treatments to patients, showing that the UK’s health service is committed to innovation and being at the cutting edge of medical products.